The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial

This phase II, multi-center, double-blinded, randomized controlled trial compared high-dose trivalent influenza vaccine to standard-dose quadrivalent influenza vaccine in children 3–17 years old who were 3–35 months post-allogeneic hematopoietic cell transplant, with each formulation administered twice, 28–42 days apart.